82 related articles for article (PubMed ID: 12203569)
1. Ones, thiones, and N-oxides: an exercise in imidazole chemistry.
Laufer S; Wagner G; Kotschenreuther D
Angew Chem Int Ed Engl; 2002 Jul; 41(13):2290-3. PubMed ID: 12203569
[No Abstract] [Full Text] [Related]
2. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.
Laufer SA; Wagner GK; Kotschenreuther DA; Albrecht W
J Med Chem; 2003 Jul; 46(15):3230-44. PubMed ID: 12852754
[TBL] [Abstract][Full Text] [Related]
3. Synthetic methodology utilized to prepare substituted imidazole p38 MAP kinase inhibitors.
Murry JA
Curr Opin Drug Discov Devel; 2003 Nov; 6(6):945-65. PubMed ID: 14758763
[TBL] [Abstract][Full Text] [Related]
4. A novel 3D-QSAR comparative molecular field analysis (CoMFA) model of imidazole and quinazolinone functionalized p38 MAP kinase inhibitors.
Sperandio da Silva GM; Sant'Anna CM; Barreiro EJ
Bioorg Med Chem; 2004 Jun; 12(12):3159-66. PubMed ID: 15158784
[TBL] [Abstract][Full Text] [Related]
5. Identification of regioisomers in a series of N-substituted pyridin-4-yl imidazole derivatives by regiospecific synthesis, GC/MS, and 1H NMR.
Wagner GK; Kotschenreuther D; Zimmermann W; Laufer SA
J Org Chem; 2003 May; 68(11):4527-30. PubMed ID: 12762762
[TBL] [Abstract][Full Text] [Related]
6. Benzimidazolone p38 inhibitors.
Dombroski MA; Letavic MA; McClure KF; Barberia JT; Carty TJ; Cortina SR; Csiki C; Dipesa AJ; Elliott NC; Gabel CA; Jordan CK; Labasi JM; Martin WH; Peese KM; Stock IA; Svensson L; Sweeney FJ; Yu CH
Bioorg Med Chem Lett; 2004 Feb; 14(4):919-23. PubMed ID: 15012994
[TBL] [Abstract][Full Text] [Related]
7. Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones.
Colletti SL; Frie JL; Dixon EC; Singh SB; Choi BK; Scapin G; Fitzgerald CE; Kumar S; Nichols EA; O'Keefe SJ; O'Neill EA; Porter G; Samuel K; Schmatz DM; Schwartz CD; Shoop WL; Thompson CM; Thompson JE; Wang R; Woods A; Zaller DM; Doherty JB
J Med Chem; 2003 Jan; 46(3):349-52. PubMed ID: 12540232
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase.
Kim DK; Lim JH; Lee JA; Dewang PM
Bioorg Med Chem Lett; 2008 Jul; 18(14):4006-10. PubMed ID: 18571921
[TBL] [Abstract][Full Text] [Related]
9. Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists.
Berlin M; Ting PC; Vaccaro WD; Aslanian R; McCormick KD; Lee JF; Albanese MM; Mutahi MW; Piwinski JJ; Shih NY; Duguma L; Solomon DM; Zhou W; Sher R; Favreau L; Bryant M; Korfmacher WA; Nardo C; West RE; Anthes JC; Williams SM; Wu RL; Susan She H; Rivelli MA; Corboz MR; Hey JA
Bioorg Med Chem Lett; 2006 Feb; 16(4):989-94. PubMed ID: 16297617
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)).
Patel CH; Dhanani S; Owen CP; Ahmed S
Bioorg Med Chem Lett; 2006 Sep; 16(18):4752-6. PubMed ID: 16870430
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of imidazo[2,1-a]phthalazines, potential inhibitors of p38 MAP kinase. Prediction of binding affinities of protein ligands.
Mavel S; Thery I; Gueiffier A
Arch Pharm (Weinheim); 2002 Jan; 335(1):7-14. PubMed ID: 11933680
[TBL] [Abstract][Full Text] [Related]
12. Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity.
Adams JL; Boehm JC; Gallagher TF; Kassis S; Webb EF; Hall R; Sorenson M; Garigipati R; Griswold DE; Lee JC
Bioorg Med Chem Lett; 2001 Nov; 11(21):2867-70. PubMed ID: 11597418
[TBL] [Abstract][Full Text] [Related]
13. Imidazopyrimidines, potent inhibitors of p38 MAP kinase.
Rupert KC; Henry JR; Dodd JH; Wadsworth SA; Cavender DE; Olini GC; Fahmy B; Siekierka JJ
Bioorg Med Chem Lett; 2003 Feb; 13(3):347-50. PubMed ID: 12565927
[TBL] [Abstract][Full Text] [Related]
14. (1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: further optimisation as highly potent and selective MSK-1-inhibitors.
Bamford MJ; Bailey N; Davies S; Dean DK; Francis L; Panchal TA; Parr CA; Sehmi S; Steadman JG; Takle AK; Townsend JT; Wilson DM
Bioorg Med Chem Lett; 2005 Jul; 15(14):3407-11. PubMed ID: 15955699
[TBL] [Abstract][Full Text] [Related]
15. Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.
Velaparthi U; Liu P; Balasubramanian B; Carboni J; Attar R; Gottardis M; Li A; Greer A; Zoeckler M; Wittman MD; Vyas D
Bioorg Med Chem Lett; 2007 Jun; 17(11):3072-6. PubMed ID: 17398093
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase.
Cogan DA; Aungst R; Breinlinger EC; Fadra T; Goldberg DR; Hao MH; Kroe R; Moss N; Pargellis C; Qian KC; Swinamer AD
Bioorg Med Chem Lett; 2008 Jun; 18(11):3251-5. PubMed ID: 18462940
[TBL] [Abstract][Full Text] [Related]
17. p38 mitogen-activated protein kinase inhibitors for the treatment of chronic cardiovascular disease.
Behr TM; Berova M; Doe CP; Ju H; Angermann CE; Boehm J; Willette RN
Curr Opin Investig Drugs; 2003 Sep; 4(9):1059-64. PubMed ID: 14582449
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of potential bisubstrate inhibitors of protein farnesyltransferase. Design and synthesis of functionalized imidazoles.
de Figueiredo RM; Coudray L; Dubois J
Org Biomol Chem; 2007 Oct; 5(20):3299-309. PubMed ID: 17912382
[TBL] [Abstract][Full Text] [Related]
19. Towards the improvement of the synthesis of novel 4(5)-aryl-5(4)-heteroaryl-2-thio-substituted imidazoles and their p38 MAP kinase inhibitory activity.
Laufer S; Koch P
Org Biomol Chem; 2008 Feb; 6(3):437-9. PubMed ID: 18219408
[TBL] [Abstract][Full Text] [Related]
20. IRAK-4 inhibitors. Part II: a structure-based assessment of imidazo[1,2-a]pyridine binding.
Buckley GM; Ceska TA; Fraser JL; Gowers L; Groom CR; Higueruelo AP; Jenkins K; Mack SR; Morgan T; Parry DM; Pitt WR; Rausch O; Richard MD; Sabin V
Bioorg Med Chem Lett; 2008 Jun; 18(11):3291-5. PubMed ID: 18482836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
